In July 2007, we reported on the issue of "late stent thrombosis" and brief threat it posed to the drug-eluting stent market (hence the title, "Drug-Eluting Stents’ Recent Woes Only a Hiccup" ).
At the time, it was determined that, despite the clear concerns about the link between drug-eluting stents and late stent thrrombosis, it was demonstrated, at data presented at the 2008 TCT meeting, that the risk was actually minimal and, in any case, not sufficient to preempt the compelling benefits offered by drug-eluting stents.
Now, a small study at University Hospital at Bern, Switzerland, examining 28 patients, found a high correlation between the incidence of late stent thrombosis and hypersensitivity (evidenced by high eosinophil infiltrates) to the drug coating the stent or, more likely, the stent polymer, resulting in remodeling occurring around the stent struts. Such hypersensitivity is considered very rare — resulting in an incidence of MI or death that is no higher than for bare metal stents, making it a non-issue in the market for DES versus bare metal stents.
MedMarket Diligence has completed a global analysis of the drug-eluting, bare metal and other coronary stents market. See report C245 for details.